Atanackovic, Djordje

Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology

Kumar, S. K., Callander, N. S., Alsina, M., Atanackovic, D., Biermann, J. S., Chandler, J. C., Costello, C., Faiman, M., Fung, H. C., Gasparetto, C., et al. (2017) · Journal of the National Comprehensive Cancer Network

Multiple Myeloma Research and TreatmentsAmyloidosis: Diagnosis, Treatment, Outcomes

Cited by 279

Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial

Usmani, S. Z., Schjesvold, F., Oriol, A., Karlin, L., Cavo, M., Rifkin, R. M., Yimer, H. A., LeBlanc, R., Takezako, N., McCroskey, R. D., et al. (2019) · The Lancet Haematology

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 251

A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer

Sebastian, M., Schröder, A., Scheel, B., Hong, H. S., Muth, A., von Boehmer, L., Zippelius, A., Mayer, F., Reck, M., Atanackovic, D., et al. (2019) · Cancer Immunology, Immunotherapy

Immunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers

Cited by 209

FOXP3 and CTLA4 overexpression in multiple myeloma bone marrow as a sign of accumulation of CD4+ T regulatory cells

Braga, W. M. T., da Silva, B. R., de Carvalho, A. C., Maekawa, Y. H., Bortoluzzo, A. B., Rizzatti, E. G., Atanackovic, D., & Colleoni, G. W. B. (2014) · Cancer Immunology, Immunotherapy

Multiple Myeloma Research and TreatmentsT-cell and B-cell Immunology

Cited by 88

Multiple myeloma and family history of lymphohaematopoietic cancers: Results from the International Multiple Myeloma Consortium

Schinasi, L. H., Brown, E. E., Camp, N. J., Wang, S. S., Hofmann, J. N., Chiu, B. C., Miligi, L., Beane Freeman, L. E., de Sanjose, S., Bernstein, L., et al. (2016) · British Journal of Haematology

Multiple Myeloma Research and TreatmentsMultiple and Secondary Primary Cancers

Cited by 57

Messenger RNA vaccination and B-cell responses in NSCLC patients.

Sebastian, M., von Boehmer, L., Zippelius, A., Mayer, F., Reck, M., Atanackovic, D., Thomas, M., Schneller, F., Stoehlmacher-Williams, J., Goekkurt, E., et al. (2012) · Journal of Clinical Oncology

Immunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers

Cited by 13